Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children

Vaccine

Volumn 31, Issue 17, 2013, Pages 2152-2155

  Raczniak, Gregory A ^a,b   Thomas, Timothy K ^c   Bulkow, Lisa R ^a   Negus, Susan E ^c   Zanis, Carolyn L ^a   Bruce, Michael G ^a   Spradling, Philip R ^d   Teshale, Eyasu H ^d   McMahon, Brian J ^a,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Alaska Native Tribal Health Consortium   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Enterovirus infections; Hepatitis A virus; Inactivated hepatitis A vaccine; RNA viruses

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS A; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; PROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84875873115     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.048     Document Type: Article

References (20)

1. Bulkow L.R., Wainwright R.B., McMahon B.J., Middaugh J.P., Jenkerson S.A., Margolis H.S. Secular trends in hepatitis A virus infection among Alaska Natives. J Infect Dis 1993, 168:1017-1020.
2. Peach D., McMahon B.J., Bulkow L., Funk E., Harpaz R., Margolis H.S. Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska. J Infect Dis 2002, 186:1081-1085.
3. McMahon B.J., Williams J., Bulkow L., Snowball M., Wainwright R., Kennedy M., et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995, 171:676-679.
4. Hammitt L.L., Bulkow L., Hennessy T.W., Zanis C., Snowball M., Williams J.L., et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008, 198:1776-1782.
5. Byrd K.K., Bruden D.L., Bruce M.G., Bulkow L.R., Zanis C.L., Snowball M.M., et al. Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years. Journal of Pediatric Infectious Diseases 2010, 5:321-327.
6. Raczniak G.A., Bulkow L.R., Bruce M.G., Zanis C.L., Baum R.L., Snowball M.M., et al. Long-term immunogenicity of hepatitis a virus vaccine in alaska 17 years after initial childhood series. J Infect Dis 2013, 207:493-496.
7. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120:e373-e381.
8. Bian G.L., Ma R., Dong H.J., Ni H.X., Hu F.J., Chen Y.R., et al. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010, 28:4798-4801.
9. Beran J., Kervyn D., Wertzova V., Hobzova L., Tichy P., Kuriyakose S., et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine 2010, 28:5993-5997.
10. van Damme P., Kafeja F., Van Der Wielen M., Leyssen M., Jacquet J.M. Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age. Pediatr Infect Dis J 2011, 30:703-705.
11. Dorell C.G., Yankey D., Byrd K.K., Murphy T.V. Hepatitis A vaccination coverage among adolescents in the United States. Pediatrics 2012, 129:213-221.
12. Singleton R.J., Hess S., Bulkow L.R., Castrodale L., Provo G., McMahon B.J. Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska. Vaccine 2010, 28:6298-6304.
13. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000, 60:1-7.
14. Chan C.Y., Lee S.D., Yu M.I., Wang Y.J., Chang F.Y., Lo K.J. Long-term follow-up of hepatitis A vaccination in children. Vaccine 1999, 17:369-372.
15. Fan P.C., Chang M.H., Lee P.I., Safary A., Lee C.Y. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 1998, 16:232-235.
16. Maiwald H., Jilg W., Bock H.L., Loscher T., Sonnenburg F. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997, 15:346-348.
17. Byrd K.K., Redd J.T., Holman R.C., Haberling D.L., Cheek J.E. Changing trends in viral hepatitis-associated hospitalizations in the American Indian/Alaska Native population, 1995-2007. Public Health Rep 2011, 126:816-825.
18. McLaughlin J, Castordale, L. Alaska Epidemiology Bulletin. 2010 Annual (January-December) Infectious Disease Report. 2011. http://www.epi.alaska.gov/bulletins/docs/b2011_07.pdf.
19. Williams J., Fox-Leyva L., Christensen C., Fisher D., Schlicting E., Snowball M., et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000, 18:1939-1943.
20. Williams J.L., Bruden D.A., Cagle H.H., McMahon B.J., Negus S.E., Christensen C.J., et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 2003, 21:3208-3211.